SCYNEXIS Inc (SCYX) stock
SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3072% below fair value
$2.85−0.06 (-2.06%)
Close on Nov 17, 2026Market cap $28.36MP/E –Yield –
Scynexis total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Scynexis's total debt was $0 at Sep 30, 2022. For fiscal 2021 it was $0. The highest annual figure on record is $15.08M in fiscal 2018.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $15.08M | +2.9% |
| FY2017 | Dec 31, 2017 | $14.65M | +2.8% |
| FY2016 | Dec 31, 2016 | $14.25M | – |
| FY2015 | Dec 31, 2015 | $0 | – |
| FY2014 | Dec 31, 2014 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $15.00M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $0 | -100.0% |
| Q4 FY2018 | Dec 31, 2018 | $15.08M | +2.9% |
| Q3 FY2018 | Sep 30, 2018 | $14.97M | +2.8% |
| Q2 FY2018 | Jun 30, 2018 | $14.86M | +2.9% |
| Q1 FY2018 | Mar 31, 2018 | $14.76M | +2.9% |
| Q4 FY2017 | Dec 31, 2017 | $14.65M | +2.8% |
| Q3 FY2017 | Sep 30, 2017 | $14.55M | +2.7% |
| Q2 FY2017 | Jun 30, 2017 | $14.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.35M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.25M | – |
| Q3 FY2016 | Sep 30, 2016 | $14.17M | – |
See a number that looks wrong?